BACKGROUND: Previous studies have shown that an increase in cost sharing by patients for medications results in reduced medication use. The purpose of our study was to determine whether the amount of members' copayments predicted oral antidiabetic treatment failure in a managed care population and to analyze the relationship between copayments, adherence to therapy, and hemoglobin A(1c) levels in patients with type-2 diabetes. METHODS: Health plan members 18 years of age or older with type-2 diabetes and who were newly initiated on an oral antidiabetic drug (OAD) between January 1, 2002, and January 31, 2006, were identified from a managed care population in the U.S. Members were required to have continuous eligibility for six or more months before and 12 months after the index prescription and were placed into four treatment groups. These patients were followed for one year. The time during which they took the index OAD was measured until treatment failure (discontinuation of therapy or a switch of the index OAD) or censoring of patient data. The medication possession ratio (MPR), which was used to calculate adherence, was defined as the number of days that a patient had a supply of the index OAD during the year after the index fill, divided by 365 days. Copays were identified for every prescription, and the amount for each 30 days of treatment was calculated. We used multivariate analyses to assess the impact of copays on treatment failure, adjusting for differences in member characteristics. RESULTS: Adherence was poor, with an overall mean MPR of 0.57, decreasing from 0.58 for the group with a copay of less than $10 to 0.52 for patients with a copay of $20 or more. Initial treatment failed for 13,091 patients (70%), with approximately 60% of all members discontinuing treatment. This discontinuation rate ranged from 55% in the lowest copayment group (below $10) to 67% in those with a copay of $30 or more. For every $10 increase in copay, OAD treatment was 26% more likely to fail (95% confidence interval, 22.3-29.8%; P < 0.0001). CONCLUSION: Higher copays for health plan members were a significant predictor of treatment failure. With the increased trend toward more cost sharing by members of health plans, ongoing evaluation will be necessary to determine the impact on treatment persistence in patients with chronic conditions.
BACKGROUND: Previous studies have shown that an increase in cost sharing by patients for medications results in reduced medication use. The purpose of our study was to determine whether the amount of members' copayments predicted oral antidiabetic treatment failure in a managed care population and to analyze the relationship between copayments, adherence to therapy, and hemoglobin A(1c) levels in patients with type-2 diabetes. METHODS: Health plan members 18 years of age or older with type-2 diabetes and who were newly initiated on an oral antidiabetic drug (OAD) between January 1, 2002, and January 31, 2006, were identified from a managed care population in the U.S. Members were required to have continuous eligibility for six or more months before and 12 months after the index prescription and were placed into four treatment groups. These patients were followed for one year. The time during which they took the index OAD was measured until treatment failure (discontinuation of therapy or a switch of the index OAD) or censoring of patient data. The medication possession ratio (MPR), which was used to calculate adherence, was defined as the number of days that a patient had a supply of the index OAD during the year after the index fill, divided by 365 days. Copays were identified for every prescription, and the amount for each 30 days of treatment was calculated. We used multivariate analyses to assess the impact of copays on treatment failure, adjusting for differences in member characteristics. RESULTS: Adherence was poor, with an overall mean MPR of 0.57, decreasing from 0.58 for the group with a copay of less than $10 to 0.52 for patients with a copay of $20 or more. Initial treatment failed for 13,091 patients (70%), with approximately 60% of all members discontinuing treatment. This discontinuation rate ranged from 55% in the lowest copayment group (below $10) to 67% in those with a copay of $30 or more. For every $10 increase in copay, OAD treatment was 26% more likely to fail (95% confidence interval, 22.3-29.8%; P < 0.0001). CONCLUSION: Higher copays for health plan members were a significant predictor of treatment failure. With the increased trend toward more cost sharing by members of health plans, ongoing evaluation will be necessary to determine the impact on treatment persistence in patients with chronic conditions.
Authors: Rajesh Balkrishnan; Rukmini Rajagopalan; Fabian T Camacho; Sally A Huston; Frederick T Murray; Roger T Anderson Journal: Clin Ther Date: 2003-11 Impact factor: 3.393
Authors: Lauren G Gilstrap; Ateev Mehrotra; Barbara Bai; Sherri Rose; Rachel A Blair; Michael E Chernew Journal: Diabetes Care Date: 2018-05-24 Impact factor: 19.112
Authors: Caitlyn T Solem; Ahmed Shelbaya; Yin Wan; Chinmay G Deshpande; Jose Alvir; Elizabeth Pappadopulos Journal: Neuropsychiatr Dis Treat Date: 2016-10-25 Impact factor: 2.570
Authors: Susan A Berry; Christine Brown; Mitzie Grant; Carol L Greene; Elaina Jurecki; Jean Koch; Kathryn Moseley; Ruth Suter; Sandra C van Calcar; Judy Wiles; Stephen Cederbaum Journal: Genet Med Date: 2013-03-07 Impact factor: 8.822
Authors: Will Maimaris; Jared Paty; Pablo Perel; Helena Legido-Quigley; Dina Balabanova; Robby Nieuwlaat; Martin McKee Journal: PLoS Med Date: 2013-07-30 Impact factor: 11.069
Authors: Manjiri D Pawaskar; Liou Xu; Yuexin Tang; Gary A Puckrein; Swapnil N Rajpathak; Bruce Stuart Journal: Diabetes Ther Date: 2018-08-24 Impact factor: 2.945